← 返回前沿论文

口腔多原发癌与单原发癌的免疫及 HPV 特征比较

英文原题:Immune and HPV landscape in oral multiple primary cancers compared to single primary cancer.

PubMed 2025/09/17(内容时间) Oral Oncol Q1 · IF 4(JCR 2025)

研究概要

MPCs 呈现出独特的免疫景观,其特征为淋巴细胞减少(尤其是 CD4+/CD20+ 亚群)和巨噬细胞富集,且不依赖于 HPV。这些发现突显了 MPCs 发病机制中潜在的免疫学机制,并可能为靶向治疗策略提供依据。

研究思路结论见上方概要

口腔鳞状细胞癌(OSCC)是最常见的头颈部肿瘤类型。值得注意的是,与口腔单原发癌(SPC)相比,OSCC患者发生的多原发癌(MPC)具有不同的临床病理和分子特征。然而,口腔MPC的免疫微环境仍缺乏充分表征,尤其是与SPC的对比研究。

我们开展了一项配对病例对照研究,使用来自30例MPC患者的60份样本和来自60例SPC患者的60份样本,按性别、生活方式因素(吸烟/饮酒)及肿瘤分期/分级进行匹配。免疫组化定量了浸润免疫细胞(CD3/CD4/CD8/CD20/CD68/CD16)、三级淋巴结构(TLS)及PD-L1表达。采用p16免疫组化(IHC)与HPV16/18原位杂交(ISH)相结合的双重检测方法确定人乳头瘤病毒(HPV)状态。

MPC中未检测到HPV感染(经p16/HPV-ISH双重确认),提示HPV非依赖性发病机制。免疫谱分析显示,与SPC相比,MPC中CD4 + T细胞(p = 0.0306)和CD20 + B细胞(p = 0.0002)显著减少,而CD68 + 巨噬细胞升高(p = 0.0008)。CD3 + T细胞、CD8 + T细胞和CD16 + NK细胞未显示组间差异(p > 0.05)。患者内分析显示,除CD4 + T细胞(p = 0.0028)外,免疫模式一致。PD-L1阳性(p = 0.568)以及肿瘤内和间质TLS频率(p = 0.241)相当,且92 %的TLS + 样本共表达PD-L1(p = 0.001)。

展开英文摘要原文

BACKGROUND: Oral squamous cell carcinoma (OSCC) is the most common type of head and neck tumor. Notably, OSCC patients develop multiple primary cancers (MPCs) with distinct clinicopathological and molecular profiles compared to oral single primary cancer (SPC). However, the immune microenvironment of oral MPCs remains poorly characterized, particularly in contrast to SPC. METHODS: We conducted a paired case-control study using 60 samples from 30 MPCs patients and 60 samples from 60 SPC patients, matched by gender, lifestyle factors (smoking/alcohol), and tumor stage/grade. Immunohistochemistry quantified infiltrating immune cells (CD3/CD4/CD8/CD20/CD68/CD16), tertiary lymphoid structures (TLS), and PD-L1 expression. Human papillomavirus (HPV) status was determined using a dual-detection approach combining p16 immunohistochemistry (IHC) and HPV16/18 in situ hybridization (ISH). RESULTS: No HPV infection was detected in MPCs (double-confirmed by p16/HPV-ISH), suggesting HPV-independent pathogenesis. Immune profiling revealed significantly reduced CD4 + T cells (p = 0.0306) and CD20 + B cells (p = 0.0002) in MPCs versus SPC, while CD68 + macrophages were elevated (p = 0.0008). CD3 + T cells, CD8 + T cells and CD16 + NK cells showed no intergroup differences (p > 0.05). Intrapatient analysis demonstrated consistent immune patterns except for CD4 + T cells (p = 0.0028). PD-L1 positivity (p = 0.568) and intratumoral and stromal TLS frequency (p = 0.241) were comparable, and 92 % TLS + samples co-expressed PD-L1 (p = 0.001). CONCLUSION: MPCs exhibit a unique immune landscape characterized by lymphocyte decrease (particularly CD4 + /CD20 + subsets) and macrophage enrichment, independent of HPV. These findings highlight potential immunological mechanisms underlying MPCs pathogenesis and may inform targeted therapeutic strategies.

论文信息

作者
Zhou X、Zhang J、Lou Y、Li W、Xu Z、Zhang H、Li T
第一作者单位
Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology & Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health & NMPA Key Laboratory for Dental Materials, Beijing, China; Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and Maxillofacial Regions, Chinese Academy of Medical Sciences (2019RU034), Beijing, China.China
通讯作者单位
Department of Oral Pathology, Peking University School and Hospital of Stomatology & National Center of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology & Research Center of Engineering and Technology for Computerized Dentistry Ministry of Health & NMPA Key Laboratory for Dental Materials, Beijing, China; Research Unit of Precision Pathologic Diagnosis in Tumors of the Oral and Maxillofacial Regions, Chinese Academy of Medical Sciences (2019RU034), Beijing, China; Laboratory of Oral Biomedicine, Henan University School of Stomatology, Kaifeng, Henan, China. Electronic address: litiejun22@vip.sina.com.China
文献类型
对照研究
期刊
Oral oncology2025 Oct
原文标识
PubMed 40966845 · DOI 10.1016/j.oraloncology.2025.107646